JOHN KIRKWOOD to BCG Vaccine
This is a "connection" page, showing publications JOHN KIRKWOOD has written about BCG Vaccine.
Connection Strength
0.620
-
Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
Score: 0.233
-
Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
Score: 0.217
-
Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
Score: 0.073
-
Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER). Cancer. 1982 Oct 01; 50(7):1299-303.
Score: 0.049
-
Adjuvant therapy of melanoma. Semin Surg Oncol. 1998 Jun; 14(4):302-10.
Score: 0.036
-
Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery. 1982 Sep; 92(3):459-63.
Score: 0.012